Journal ArticleDOI
B cell elimination in systemic lupus erythematosus
João Furtado,David A. Isenberg +1 more
TLDR
This review will focus on results of B cell direct depletion in the treatment of patients with systemic lupus erythematosus and the results from randomized controlled studies have been disappointing.About:
This article is published in Clinical Immunology.The article was published on 2013-02-01. It has received 42 citations till now. The article focuses on the topics: Rituximab & Cyclophosphamide.read more
Citations
More filters
Journal ArticleDOI
Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)
TL;DR: Both atacicept doses were associated with reductions in total Ig levels and anti-dsDNA antibodies, and increases in C3 and C4 levels, and most treatment-emergent adverse events were mild or moderate.
Journal ArticleDOI
The role of innate and adaptive immunity in Parkinson's disease.
TL;DR: The role of immunity and inflammation in the onset and progression of Parkinson's disease is investigated in this article. But, the role of immune system involvement on disease progression has not yet been clarified.
The role of innate and adaptive immunity in parkinsons disease
TL;DR: The evidence supporting the potential efficacy of immunomodulatory therapies in PD prevention or treatment is reviewed, with a clear need for additional research to clarify the role of immunity and inflammation in this chronic, neurodegenerative disease.
Journal ArticleDOI
The BAFFling effects of rituximab in lupus: danger ahead?
TL;DR: It is argued that B-cell depletion should be swiftly followed by BAFF inhibition in patients with SLE, because repeated rituximab infusions can result in a feedback loop characterized by ever-rising BAFF levels, surges in autoantibody production and worsening of disease.
Journal ArticleDOI
High-risk pregnancy and the rheumatologist
TL;DR: The highest-risk pregnancies and controversial areas, the types of maternal and fetal complications, the treatments that can be used in pregnancy (and breastfeeding) and longer-term outcomes that could affect the mother are discussed.
References
More filters
Journal ArticleDOI
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
Sandra V. Navarra,Renato Guzman,Alberto E. Gallacher,Stephen B. Hall,Roger A. Levy,Renato E. Jimenez,Edmund K. Li,Mathew Thomas,Ho-Youn Kim,Manuel G. León,Coman Tanasescu,Eugeny L. Nasonov,Joung-Liang Lan,Lilia Pineda,Z. John Zhong,William W. Freimuth,Michelle A. Petri +16 more
TL;DR: The efficacy and safety of the fully human monoclonal antibody belimumab (BLyS-specific inhibitor) was assessed in patients with active systemic lupus erythematosus in a multicentre phase 3 study done in Latin America, Asia-Pacific, and eastern Europe.
Journal ArticleDOI
Efficacy and Safety of Rituximab in Moderately-to-Severely Active Systemic Lupus Erythematosus: The Randomized, Double-Blind, Phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial
Joan T. Merrill,C. Michael Neuwelt,Daniel J. Wallace,Joseph C. Shanahan,Kevin Latinis,Jim C. Oates,Tammy O. Utset,Caroline Gordon,David A. Isenberg,Hsin Ju Hsieh,David Zhang,Paul Brunetta +11 more
TL;DR: The EXPLORER trial enrolled patients with moderately-to-severely active SLE and used aggressive background treatment and sensitive cutoffs for nonresponse, and no differences were noted between placebo and rituximab in the primary and secondary end points.
Journal ArticleDOI
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study†
Brad H. Rovin,Richard Furie,Kevin Latinis,R. John Looney,Fernando C. Fervenza,Jorge Sánchez-Guerrero,Romeo Maciuca,David Zhang,J Garg,Paul Brunetta,Gerald B. Appel +10 more
TL;DR: Although rituximab therapy led to more responders and greater reductions in anti-dsDNA and C3/C4 levels, it did not improve clinical outcomes after 1 year of treatment.
Journal ArticleDOI
Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis
Ellen M. Ginzler,Mary Anne Dooley,Cynthia Aranow,Mimi Y. Kim,Jill P. Buyon,Joan T. Merrill,Michelle Petri,Gary S. Gilkeson,Daniel J. Wallace,Michael H. Weisman,Gerald B. Appel +10 more
TL;DR: In this 24-week randomized, open-label, noninferiority trial, mycophenolate mofetil was more effective than intravenous cyclophosphamide in inducing remission of lupus nephritis and had a more favorable safety profile.
Journal ArticleDOI
B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab
R. John Looney,Jennifer H. Anolik,Debbie Campbell,Raymond E. Felgar,Faith Young,Lois J. Arend,James A. Sloand,Joseph D. Rosenblatt,Iñaki Sanz +8 more
TL;DR: Rituximab therapy appears to be safe for the treatment of SLE and holds significant therapeutic promise, at least for the majority of patients experiencing profound B cell depletion.